<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419948</url>
  </required_header>
  <id_info>
    <org_study_id>79549/16-05-2019</org_study_id>
    <nct_id>NCT04419948</nct_id>
  </id_info>
  <brief_title>Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM</brief_title>
  <official_title>Acute Effect of Oleocanthal Rich Extra-virgin Olive Oil on Postpranial Hyperglycemia and Platelet Activation of T2DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harokopio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Peloponnese</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harokopio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot acute dietary intervention study with a randomized cross-over design aiming
      to investigate whether acute supplementation of extra virgin olive oil (EVOO) rich in
      oleocanthal could attenuate postprandial hyperglycemia and activation of platelets in T2DM
      patients. For this reason, non-insulin dependent diabetic patients (10-15) will be randomly
      assigned to consume in five different days white bread (50 g CHO) with butter, butter with
      ibuprofen, refined olive oil and olive oil with oleocanthal (250 mg/Kg 500 mg/Kg). Blood
      samples will be collected pre- and post-intervention up to 4 hours in order to determine
      platelet aggregation, postprnadial glycemia, lipemia, inflammation and oxidative stress.

      Taking into account the strong anti-inflammatory and anti-platelet properties of oleocanthal,
      this study will assess whether oleocanthal-rich olive oils could exert similar effects under
      real in vivo conditions in T2DM patients. It will also assess whether these effects are
      achieved through improvement of postprandial glycemia and lipemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Acute postprandial study with a randomized cross-over design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of ADP-induced platelet aggregation at 90 min after meals consumption</measure>
    <time_frame>0 and 90 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of ADP induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of ADP-induced platelet aggregation at 240 min after meals consumption</measure>
    <time_frame>0 and 240 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of ADP induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of TRAP-induced platelet aggregation at 90 min after meals consumption</measure>
    <time_frame>0 and 90 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of TRAP induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of TRAP-induced platelet aggregation at 240 min after meals consumption</measure>
    <time_frame>0 and 240 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of TRAP induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of PAF-induced platelet aggregation at 90 min after meals consumption</measure>
    <time_frame>0 and 90 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of PAF induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of PAF-induced platelet aggregation at 240 min after meals consumption</measure>
    <time_frame>0 and 240 after the consumption of each type of meal</time_frame>
    <description>EC50 (microM) of PAF induced platelet aggregation will be assessed by light transmittance aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Glucose</measure>
    <time_frame>0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal</time_frame>
    <description>iAUC of postprandial glucose will be calculated by serum glucose levels (mg/dL) which will be assessed by commercially available kits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Insulin</measure>
    <time_frame>0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal</time_frame>
    <description>iAUC of postprandial insulin will be calculated by serum insulin levels (mIU/L) which will be assessed by commercially available kits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Triglycerides</measure>
    <time_frame>0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal</time_frame>
    <description>iAUC of postprandial triglycerides will be calculated by serum triglyceride levels (mg/dL) which will be assessed by commercially available kits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of IL-6</measure>
    <time_frame>0, 60, 120, 180, 240 min after the consumption of each meal</time_frame>
    <description>iAUC of postprandial IL-6 will be calculated by serum IL-6 levels (mg/dL) which will be assessed by commercially available ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under the Plasma Concentration Versus Time Curve (AUC) of Protein Carbonyls</measure>
    <time_frame>0, 60, 120, 180, 240 min after the consumption of each meal</time_frame>
    <description>iAUC of postprandial protein carbonyls will be calculated by plasma protein carbonyl levels (mg/dL) which will be determined by a photometric assay</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Diabetes Mellitus, Adult-Onset</condition>
  <condition>Platelet Dysfunction</condition>
  <condition>Postprandial Hyperglycemia</condition>
  <condition>Lipidemia</condition>
  <condition>Inflammation</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100g white bread plus 40ml butter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100g white bread plus 40ml butter and 400mg ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refined olive oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100g white bread plus 40ml refined olive oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVOO with moderate concentration of oleocanthal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVOO with high concentration of oleocanthal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>White bread</intervention_name>
    <description>White bread (120g) containing 54 g CHO</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>EVOO with high concentration of oleocanthal</arm_group_label>
    <arm_group_label>EVOO with moderate concentration of oleocanthal</arm_group_label>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_label>Refined olive oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Butter</intervention_name>
    <description>Butter 39 g</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Refined olive oil</intervention_name>
    <description>Refined olive oil (40 ml).</description>
    <arm_group_label>Refined olive oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVOO with 250 mg/kg oleocanthal</intervention_name>
    <description>Extra virgin olive oil containing 250 mg/kg oleocanthal.</description>
    <arm_group_label>EVOO with moderate concentration of oleocanthal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVOO with 500 mg/kg oleocanthal</intervention_name>
    <description>Extra virgin olive oil containing 500 mg/kg oleocanthal.</description>
    <arm_group_label>EVOO with high concentration of oleocanthal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400 mg</description>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients diagnosed with T2DM

          -  stable weight the last two months

          -  smokers or not

          -  no restriction regarding the menopause

        Exclusion Criteria:

          -  insulin therapy

          -  antiplatelet, anti-coagulant, anti-inflammatory and anti-depressant medication

          -  chronic inflammatory disease

          -  autoimmune diseases

          -  cancer

          -  uncontrolled thyroid disease.

          -  supplement consumption the last two months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tzortzis Nomikos, PhD</last_name>
    <phone>00302109358920</phone>
    <email>tnomikos72@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Efthymia Katsa, MSc</last_name>
    <phone>00306977973450</phone>
    <email>merfykatsa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nutrition and Dietetics, Harokopio University</name>
      <address>
        <city>Athens</city>
        <state>I Am Not In The U.S. Or Canada</state>
        <zip>17671</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tzortzis Nomikos, PhD</last_name>
      <phone>00302109358920</phone>
      <email>tnomikos@hua.gr</email>
    </contact>
    <contact_backup>
      <last_name>Maria Efthymia Katsa, MSc</last_name>
      <phone>00306977973450</phone>
      <phone_ext>Nomikos</phone_ext>
      <email>tnomikos72@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tzortzis Nomikos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Efthymia Katsa, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kleopatra Ketselidi, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Agrawal K, Melliou E, Li X, Pedersen TL, Wang SC, Magiatis P, Newman JW, Holt RR. Oleocanthal-rich extra virgin olive oil demonstrates acute anti-platelet effects in healthy men in a randomized trial. J Funct Foods. 2017 Sep;36:84-93. doi: 10.1016/j.jff.2017.06.046. Epub 2017 Jul 3.</citation>
    <PMID>29904393</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harokopio University</investigator_affiliation>
    <investigator_full_name>Tzortzis Nomikos</investigator_full_name>
    <investigator_title>Assistant Professor of Biochemistry</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>diabetic platelet</keyword>
  <keyword>platelet aggregation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <keyword>postrpandial</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>extra virgin olive oil</keyword>
  <keyword>oleocanthal</keyword>
  <keyword>polyphenols</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

